DPP-4

Cat. No.

A43486

CAS No.

1339955-03-1

Sitagliptin fenilalanil

Sitagliptin fenilalanil is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor that plays a crucial role in the regulation of glucose metabolism. By blocking the activity of DPP-4, it increases levels of incretin hormones, which enhance insulin secretion in response to meals and reduce glucagon levels. This compound is primarily utilized in diabetes research to explore therapeutic strategies for improving glycemic control and understanding the mechanisms of insulin regulation.

Cat. No.

A43487

CAS No.

625110-37-4

TS-021 free base

Synonyms: DPP-IV-IN-1

TS-021 free base is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV), a serine protease with a crucial role in glucose metabolism and immune regulation, exhibiting an IC50 of 4.6 nM. This compound is of significant interest in diabetes research and immune modulation studies, as DPP-IV inhibitors can enhance insulin secretion and improve glycemic control. TS-021 free base is valuable for investigations aimed at understanding DPP-IV's role in metabolic disorders and therapeutic applications.

Cat. No.

A43488

CAS No.

90614-49-6

Diprotin B

Diprotin B is an inhibitor of dipeptidyl peptidase IV (DPP IV). By exhibiting competitive inhibition, Diprotin B mimics substrate behavior due to its tripeptide structure, particularly the presence of a proline residue at the penultimate position. This compound is utilized in research to study the modulation of glucose metabolism and to explore potential therapeutic applications in diabetes and related metabolic disorders.

Cat. No.

A43489

CAS No.

1403496-40-1

Fotagliptin benzoate

Synonyms: SAL067

Fotagliptin benzoate is a potent Dipeptidyl Peptidase IV (DPP-4) inhibitor with an IC50 value of 2.27 nM. It demonstrates a favorable safety profile in both rat and canine models. This compound is primarily utilized in research related to Type 2 diabetes mellitus, providing insights into glucose metabolism and potential therapeutic interventions.

Cat. No.

A43490

CAS No.

1152810-23-5

Sheng Gelieting

Synonyms: CGT-8012

Sheng Gelieting (CGT-8012) is a selective dipeptidyl peptidase IV (DP-IV) inhibitor with notable activity, exhibiting an IC50 value of 87 nM. This compound is primarily used in research focused on metabolic diseases, particularly type 2 diabetes, by modulating insulin signaling and glucose homeostasis. Sheng Gelieting is instrumental in studies aimed at elucidating the role of DP-IV in glucose metabolism and the development of related therapeutic strategies.

Cat. No.

A43491

CAS No.

529-51-1

Azaleatin

Azaleatin is an O-methylated flavonol that acts as a dipeptidyl peptidase-IV (DPP-IV) inhibitor. This compound has been implicated in the regulation of glucose metabolism and exhibits potential in the management of type-2 diabetes and obesity. Research applications include the exploration of metabolic disorders and the development of therapeutic strategies targeting DPP-IV pathways.

Cat. No.

A43492

CAS No.

1613458-79-9

Propyl-GSK-2793660 hydrochloride

Propyl-GSK-2793660 hydrochloride is an irreversible and covalent inhibitor of Dipeptidyl Peptidase I (DPP1). This compound demonstrates significant inhibition of DPP1 activity, making it a valuable tool for investigating mechanisms related to bronchiectasis. Its application in research may facilitate the understanding of DPP1's role in various biological processes and potential therapeutic avenues.

Cat. No.

A43493

CAS No.

1312954-58-7

Fotagliptin

Synonyms: SAL067 free base

Fotagliptin is a potent Dipeptidyl Peptidase IV (DPP-4) inhibitor with an IC50 of 2.27 nM. This compound is characterized by its favorable safety profile in rodent and canine models. Fotagliptin is primarily utilized in research related to Type 2 diabetes mellitus, contributing to investigations aimed at understanding glycemic control and insulin secretion mechanisms.

Cat. No.

A43494

CAS No.

1339954-75-4

Sitagliptin fenilalanil hydrochloride

Sitagliptin fenilalanil hydrochloride is a potent inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme involved in glucose metabolism. By blocking DPP-4 activity, this compound enhances the levels of incretin hormones, which promotes insulin secretion and lowers glucagon levels, thereby improving glycemic control. It is primarily used in research applications related to diabetes mellitus and metabolic disorders.

Cat. No.

A43496

CAS No.

1036959-27-9

(2R)-Vildagliptin

Synonyms: (2R)-LAF237; (2R)-NVP-LAF 237

(2R)-Vildagliptin is the isomer of Vildagliptin and serves as an essential experimental control in research. As a selective dipeptidyl peptidase IV (DPP-IV) inhibitor, Vildagliptin exhibits potent antihyperglycemic activity, with an IC50 of 3.5 nM in human Caco-2 cells. This compound is utilized in studies related to diabetes and metabolic disorders, highlighting its significance in exploring therapeutic interventions for glucose regulation.

Cat. No.

A43498

CAS No.

1017682-66-4

PK44 phosphate

PK44 phosphate is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV) with an IC50 value of 15.8 nM. It plays a critical role in regulating glucose metabolism and has potential applications in the treatment of type 2 diabetes. PK44 phosphate may also be used in pharmacological studies to explore the therapeutic effects of DPP-IV inhibition.

Cat. No.

A43499

CAS No.

5092-09-1

Saikogenin A

Saikogenin A is a potent dipeptidyl peptidase-IV (DPP-IV) inhibitor derived from the traditional Chinese herbal plant Tsai-Fu. This compound exhibits significant biological activity in regulating glucose metabolism and improving insulin sensitivity, making it a valuable tool for diabetes research. Its potential applications extend to studies on metabolic disorders and the exploration of therapeutic options for type 2 diabetes management.

Cat. No.

A43507

CAS No.

1404559-15-4

(2S,4R)-Teneligliptin

(2S,4R)-Teneligliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4). By enhancing the plasma concentration of active glucagon-like peptide-1 (GLP-1), it promotes insulin secretion in response to elevated blood glucose levels, demonstrating significant hypoglycemic activity. This compound holds promise for research applications focused on type 2 diabetes management and related metabolic disorders.

Cat. No.

A43508

CAS No.

1254318-44-9

AZD5248

AZD5248 is a selective inhibitor of dipeptidyl peptidase 1 (DPP1), a key enzyme involved in the regulation of peptide homeostasis. This compound demonstrates significant biological activity in the modulation of immune responses and is particularly relevant for research in chronic obstructive pulmonary disease (COPD) and other inflammatory lung disorders. Its ability to inhibit DPP1 makes it a valuable tool for investigating the therapeutic potential in respiratory diseases.

Cat. No.

A43510

CAS No.

1174038-86-8

Retagliptin hydrochloride

Synonyms: SP2086 hydrochloride

Retagliptin hydrochloride is an effective inhibitor of dipeptidyl peptidase-4 (DPP-4), a key enzyme in glucose metabolism. This compound enhances glycemic control in type 2 diabetes by prolonging the action of incretin hormones, including glucagon-like peptide-1 (GLP-1). It is utilized in research applications focused on metabolic disorders and the regulation of insulin secretion.

Cat. No.

A43511

CAS No.

2243737-33-7

Cetagliptin

Cetagliptin is an orally active dipeptidyl peptidase 4 (DPP-4) inhibitor that also engages CYP2D6 with an IC50 value of 6 µM. By inhibiting DPP-4, cetagliptin effectively reduces the degradation of glucagon-like peptide-1 (GLP-1), contributing to the regulation of postprandial blood glucose levels. This compound is primarily utilized in type 2 diabetes mellitus research, making it a valuable tool for studying glucose homeostasis and metabolic responses.

Cat. No.

A43512

CAS No.

1246960-27-9

Evogliptin hydrochloride

Synonyms: DA-1229 hydrochloride

Evogliptin hydrochloride is a potent and selective inhibitor of Dipeptidyl Peptidase-4 (DPP-4), primarily utilized to enhance glycemic control in the management of type 2 diabetes. Its mechanism involves significant and sustained hypoglycemic effects while also reducing inflammatory and fibrotic signals in hepatocytes through the induction of autophagy. This compound is relevant for research exploring metabolic disorders, including type 2 diabetes, renal impairment, osteoporotic changes, and chronic liver inflammation.

Cat. No.

A43513

CAS No.

890402-81-0

Dutogliptin tartrate

Synonyms: PHX-1149

Dutogliptin tartrate is a potent and selective dipeptidyl peptidase-4 (DPP4) inhibitor. It demonstrates significant biological activity in the modulation of incretin hormones, thereby enhancing insulin secretion and lowering glucose levels. This compound is primarily utilized in research focused on the management and treatment of type 2 diabetes mellitus, contributing to the understanding of glucose metabolism and the role of DPP4 in diabetic pathophysiology.

Cat. No.

A43514

CAS No.

1359670-56-6

Anagliptin hydrochloride

Synonyms: SK-0403 hydrochloride

Anagliptin hydrochloride is a potent and selective inhibitor of dipeptidyl peptidase 4 (DPP-4), exhibiting an IC50 of 3.8 nM. It demonstrates reduced selectivity for DPP-8 and DPP-9, with IC50 values of 68 nM and 60 nM, respectively. This compound is utilized in research focused on glycemic control and has applications in studying Type 2 diabetes and related metabolic disorders.

Cat. No.

A43516

CAS No.

3020859-44-0

DPP9-IN-2

DPP9-IN-2 is a selective, potent inhibitor of Dipeptidyl Peptidase 9 (DPP9), exhibiting an IC50 of 12.9 nM. It demonstrates a selectivity index of 59 over DPP8 and shows minimal inhibitory effects on related peptidases, including DPP2, DPP4, FAP, and PREP. DPP9-IN-2 has been shown to induce pyroptosis in cancer cells and exhibits weak synergistic anti-HIV-1 activity when combined with non-nucleoside reverse transcriptase inhibitors. This compound is suitable for research related to cancer and infectious diseases.

Cat. No.

A43517

CAS No.

207556-62-5

NVP-DPP728 dihydrochloride

NVP-DPP728 dihydrochloride is a selective and potent inhibitor of dipeptidyl peptidase IV (DPP-IV), with a Ki value of 11 nM. This compound plays a critical role in the regulation of glucose metabolism and is utilized in research related to diabetes mellitus. NVP-DPP728 dihydrochloride offers valuable insights into the therapeutic potential of DPP-IV inhibition in glycemic control and metabolic diseases.

Cat. No.

A43518

CAS No.

1601480-12-9

ZY15557

ZY15557 is a novel competitive DPP-4 inhibitor with a Ki of 5.53 nM, demonstrating significant potency in inhibiting plasma DPP-4 activity. This orally active compound is useful in the investigation of type 2 diabetes and its potential therapeutic strategies. Research applications include studying glucose metabolism and insulin secretion modulation associated with DPP-4 inhibition.

Cat. No.

A43519

CAS No.

929105-33-9

RBx-0597

RBx-0597 is a selective inhibitor of Dipeptidyl Peptidase IV (DPP-IV), exhibiting IC50 values of 32 nM, 31 nM, and 39 nM for human, mouse, and rat plasma DPP-IV, respectively. This compound shows promise in the investigation of type 2 diabetes by modulating glucose metabolism and incretin levels, making it a valuable tool for diabetes research and related metabolic studies.

Cat. No.

A43520

CAS No.

54495-98-6

O-Benzoylhydroxylamine

O-Benzoylhydroxylamine is a selective inhibitor of Dipeptidyl Peptidase IV (DPP-IV), a key enzyme involved in glucose metabolism. By inhibiting DPP-IV, this compound exhibits significant anti-diabetic effects, making it valuable for research into diabetes management and related metabolic disorders. Its mechanisms and targets are critical for understanding the pathways influenced by DPP-IV inhibition.

Cat. No.

A43521

CAS No.

851389-35-0

ASP4000 hydrochloride

ASP4000 hydrochloride is a potent, selective inhibitor of dipeptidyl peptidase IV (DPP4), exhibiting an IC50 value of 2.25 nM against human recombinant DPP4. This compound demonstrates significant antihyperglycemic effects, making it valuable in studies related to type 2 diabetes research. Its oral bioavailability and competitive inhibition profile allow for potential applications in understanding DPP4's role in glucose metabolism and diabetes management.